Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Maria Stevenson

Nurse Practitioner Deerfield Beach, FL Nurse Practitioner

NPI 1194586966 CMS profile 11553190

201 E Sample Rd, Deerfield Beach, FL 33064

Open in the dashboard

General payments

$4,466

193 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Stevenson of Deerfield Beach, FL is reported in the CMS Open Payments database as having received $4,466 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,211 140
2024 General $1,080 47
2023 General $71 4
2022 General $104 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Stevenson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Maria Stevenson were reported at $3,211. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Maria Stevenson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $104 $152 $48–$470 $149
2023 $71 $166 $54–$529 $160
2024 $1,080 $173 $55–$556 $164
2025 $3,211 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Merck Sharp & Dohme Corporation $513 22 payments
  2. AstraZeneca Pharmaceuticals LP $469 17 payments
  3. Novartis Pharmaceuticals Corporation $248 11 payments
  4. Genzyme Corporation $241 10 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $229 6 payments
  6. Janssen Biotech, Inc. $214 14 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $184 7 payments
  8. Genentech USA, Inc. $176 7 payments
  9. Pfizer Inc. $153 13 payments
  10. Celgene Corporation $151 11 payments
  11. Other $1,888 75 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,282 191 payments
  2. Education $184 2 payments
Products named General payments · program years 2022–2025
  1. KEYTRUDA $490 21 payments
  2. Nubeqa $229 6 payments
  3. REBLOZYL $203 13 payments
  4. SARCLISA $185 8 payments
  5. VERZENIO $136 3 payments
  6. KISQALI $107 5 payments
  7. Orserdu $102 4 payments
  8. WELIREG $99 4 payments
  9. DATROWAY $98 1 payment
  10. ERLEADA $97 6 payments
  11. Other $3,060 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record